Signal-to-Scale™: A Strategic Marketing Framework for Biotech and Tech Companies

Why Science and Tech Companies Need a Different Framework

Biotech and deep tech companies face a specific set of go-to-market challenges that most marketing playbooks ignore:

• Multiple buyer types at once. A single sales cycle might involve a bench scientist evaluating technical specs, a VP weighing budget, and a board member asking about defensibility.
• Long, non-linear sales cycles. Pilot programs, regulatory considerations, and procurement timelines don't move at software speed.
• Credibility is the product, before the product is. Overstate a claim and you lose the room. Scientific and technical audiences are trained to spot marketing gloss immediately.
• Fundraising and commercial narratives have to coexist. The story that gets a Series A term sheet isn't automatically the story that gets a hospital system or a pharma partner to sign.

Signal-to-Scale is built around these realities instead of around generic funnel stages borrowed from B2C playbooks.

The Four Stages of Signal-to-Scale

1. Signal

Before any messaging gets written, the work starts with listening. What is the market actually telling you? This stage pulls together competitive intelligence, customer conversations, investor feedback, and category trends to identify where real demand exists, not where a company hopes it exists.

For science and tech companies, signal often shows up in unexpected places: a competitor's funding round that reveals where investor appetite is heading, a shift in funding priorities at major research agencies, or a pattern in the objections a sales team keeps hearing on discovery calls.

2. Segment

Not every account, condition, or use case deserves equal investment. This stage narrows the addressable market into segments worth pursuing first, based on willingness to pay, urgency of need, and strategic fit, rather than total addressable market size alone.

For an earlier-stage biotech, this might mean choosing which therapeutic area or research application to lead with. For a growth-stage medtech company, it might mean identifying which health system profile converts fastest and building a repeatable playbook around it.

3. Story

This is where technical differentiation gets translated into a narrative that lands with each audience, without diluting the science. A story built for investors emphasizes market size and defensibility. A story built for a clinical buyer emphasizes outcomes and workflow fit. Both need to be true at once, and both need to trace back to the same underlying data.

Getting this stage wrong is the most common failure point. Companies either oversimplify and lose credibility with technical buyers, or over-explain and lose everyone else. Signal-to-Scale treats story as a discipline, not a tagline exercise.

4. Scale

The final stage is where strategy becomes repeatable execution: content, campaigns, pipeline programs, and investor relations infrastructure that can run without reinventing the wheel every quarter. This is also where most internal marketing efforts stall, because building a sustainable engine takes different skills than building the initial narrative.

How This Differs from a Traditional Marketing Funnel

A traditional funnel (awareness, consideration, decision) assumes a single buyer moving in one direction. Signal-to-Scale assumes something closer to reality for science and tech companies: multiple audiences, moving at different speeds, often needing the same underlying evidence packaged in different ways. It's less a funnel and more a system that keeps market intelligence, segmentation, narrative, and execution connected to each other, so that a shift in one, say, a new competitor entering a segment, updates the others instead of leaving them stale.

Applying Signal-to-Scale to Your Company

The framework scales down as easily as it scales up. An early-stage company might move through Signal and Segment quickly with a small set of target accounts and a lean story built for fundraising conversations. A growth-stage company with an established product might spend more time in the Scale stage, building out repeatable pipeline and content programs across multiple buyer segments at once.

What stays constant is the sequence. Skipping Signal and jumping straight to Story is how companies end up with messaging that sounds good in a pitch deck but doesn't hold up against a technical buyer's questions.

Frequently Asked Questions

What is Signal-to-Scale™?

Signal-to-Scale is a four-stage marketing framework, Signal, Segment, Story, Scale, developed by Markeny for biotech, medtech, and technology companies to move from market intelligence to commercial growth.

Who is Signal-to-Scale designed for?

It's built for science and technology companies navigating complex buyer groups, including bench scientists, procurement teams, clinical stakeholders, and investors, where a single messaging approach doesn't work across all audiences.

How is Signal-to-Scale different from a traditional marketing funnel?

Traditional funnels assume one buyer moving through linear stages. Signal-to-Scale accounts for multiple buyer types moving at different speeds, connecting market intelligence, segmentation, narrative, and execution so they stay aligned as conditions change.